Mucosal vaccines: Non toxic derivatives of LT and CT as mucosal adjuvants

Vaccine

Volumn 19, Issue 17-19, 2001, Pages 2534-2541

  Pizza, M ^a   Giuliani, M M ^a   Fontana, M R ^a   Monaci, E ^a   Douce, G ^b   Dougan, G ^c   Mills, K H G ^d   Rappuoli, R ^a   Del Giudice, G ^a  

^a CHIRON VACCINES   (Italy)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Detoxified derivatives of CT and LT; LTK63; LTR72; Mucosal adjuvants; Mucosal vaccines

Indexed keywords

BACTERIAL TOXIN; CHOLERA TOXIN; VACCINE;

ANIMAL MODEL; ANTIBODY PRODUCTION; BACTERIAL INFECTION; BACTERIUM MUTANT; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ESCHERICHIA COLI; GENE LOCUS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION CONTROL; MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SITE DIRECTED MUTAGENESIS; TOXICITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; BINDING SITES; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; HUMANS; IMMUNITY, MUCOSAL; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINES;

EID: 0035925592     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00553-3     Document Type: Conference Paper

References (80)

1. Cholera toxin genes: Nucleotide sequence, deletion analysis and vaccine development
2. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin
3. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
4. Properties of homogeneous heat-labile enterotoxin from Escherichia coli
5. Cholera toxin and its subunits as potential oral adjuvants
6. Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant
7. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant
8. Development of a mouse model of Helicobacter pylori infection that mimics human disease
9. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection
10. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin
11. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
12. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
13. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
14. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
15. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
16. Amino acid sequence homology between cholera toxin and Escherichia coli heat-labile toxin
17. Sequence homologies between A subunits of Escherichia coli and Vibrio cholerae enterotoxins
18. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli
19. Refined structure of Escherichia coli heat-labile enterotoxin, a close relative of cholera toxin
20. Comparison of the B-pentamers of heat-labile enterotoxin and verotoxin-1: Two structures with remarkable similarity and dissimilarity
21. Heat-labile enterotoxin in Escherichia coli. Kinetics of association of subunits into periplasmic holotoxin
22. Tissue receptor for cholera exotoxin: Postulated structure from studies with GM1 ganglioside and related glycolipids
23. Binding specificities of heat-labile enterotoxins isolated from porcine and human enterotoxigenic Escherichia coli for different gangliosides
24. Comparison of the glycolipid-binding specificities of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: Identification of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant rabbit small intestine
25. Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin
26. Comparison of receptors for cholera and Escherichia coli enterotoxins in human intestine
27. Characterization of the receptor for cholera toxin and Escherichia coli heat-labile toxin in rabbit intestinal brush borders
28. Unexpected carbohydrate cross-binding by Escherichia coli heat-labile enterotoxin. Recognition of human and rabbit target cell glycoconjugates in comparison with cholera toxin
29. Identification of errors among database sequence entries and comparison of correct amino acid sequences for the heat-labile enterotoxins of Escherichia coli and Vibrio cholerae
30. Origin of the enzymatically active A1 fragment of cholera toxin
31. Vibrio cholerae hemagglutinin/protease nicks cholera enterotoxin
32. Actions of cholera toxin and the prevention and treatment of cholera
33. NAD: Arginine mono-ADP-ribosyltransferases from animal cells
34. Cholera toxin-catalyzed [32P]ADP-ribosylation of proteins
35. Intestinal electrolyte transport and diarrheal disease (2)
36. Three conserved consensus sequences identify the NAD-binding site of ADP-ribosylating enzymes, expressed by eukaryotes, bacteria and T-even bacteriophages
37. Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity
38. Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin
39. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity
40. Glutamic acid-112 of the A subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli is important for ADP-ribosyltransferase activity
41. Stimulation of choleragen enzymatic activities by GTP and two soluble proteins purified from bovine brain
42. ARF: A key regulatory switch in membrane traffic and organelle structure
43. Structure and function of ARF proteins: Activators of cholera toxin and critical components of intracellular vesicular transport processes
44. Arf proteins: The membrane traffic police?
45. Interaction of ADP-ribosylation factor with Escherichia coli enterotoxin that contains an inactivating lysine 112 substitution
46. Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors
47. Imaging the intracellular trafficking and state of the AB5 quaternary structure of cholera toxin
48. Transport of an external Lys-Asp-Glu-Leu (KDEL) protein from the plasma membrane to the endoplasmic reticulum: Studies with cholera toxin in Vero cells
49. Evidence in vivo for autogenous control of the cyclic AMP receptor protein gene (crp) in Escherichia coli by divergent RNA
50. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
51. Probing the structure-activity relationship of Escherichia coli LT-A by site-directed mutagenesis
52. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit
53. Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit
54. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
55. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin
56. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
57. Mucosal immunogenicity of genetically detoxified derivatives of heat labile toxin from Escherichia coli
58. Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin
59. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop
60. Crystal structure of a non-toxic mutant of heat-labile enterotoxin, which is a potent mucosal adjuvant
61. IEM101, a naturally attenuated Vibrio cholerae strain as carrier for genetically detoxified derivatives of cholera toxin
62. Role of trypsin-like cleavage at arginine 192 in the enzymatic cytotonic activities of Escherichia coli heat-labile enterotoxin
63. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants
64. Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides
65. The adjuvant effect of a non-toxic mutant of heat-labile enterotoxin of Escherichia coli for the induction of measles virus-specific CTL responses after intranasal co-immunization with a synthetic peptide
66. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
67. Modulation of innate and acquired immune responses by Escherichia coli heat-labile toxin: Distinct pro- and anti-inflammatory effects of the nontoxic AB complex and the enzyme activity
68. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice
69. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity, which is stronger than that with traditional intramuscular immunization
70. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs
71. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses
72. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections
73. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant
74. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection
75. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
76. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4
77. Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor beta1 and beta2 chain expression
78. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression
79. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin